Why JPMorgan Is Bullish On American Express, Bearish On Rocket Companies
Multiples of consumer finance companies rebounded in 2023, along with a broader rally in the stock market.
Goldman’s Symphony Of Ratings: Asset Management Moves For A Dynamic 2024
Goldman Sachs analyst Alexander Blostein revised the rating on several asset management stocks amid an updated outlook for American Capital Markets.
There’s Uncertainty Around Apple’s Patent Appeal For Watch, Masimo’s Royalty Exposure Is Priced In – Analyst Downgrades
Needham downgraded Masimo Corporation (NASDAQ: MASI), noting that though Apple Inc (NASDAQ: AAPL) royalties are not certain, but are mostly priced into MASI shares.
This Analyst Downgrades Bristol-Myers Squibb, Cautions Amid Product Launch And Revenue Concerns
BofA Securities downgraded Bristol-Myers Squibb & Co (NYSE: BMY), noting that initially, the analyst believed that Bristol's loss of exclusivity (LOEs) for drugs like Eliquis and Opdivo was widely understood and it was anticipated that new product lineup would compensate
Why This Goldman Sachs Analyst Is Downgrading Auto Suppliers
The auto industry has been in focus, with EV makers gaining attention.
SoFi Stock Is Sliding Wednesday: What’s Going On?
SoFi Technologies Inc (NASDAQ: SOFI) shares are trading lower Wednesday following an analyst downgrade from Keefe, Bruyette & Woods.
These Are Key Stocks in Cloud and Analytics for Savvy Tech Investments – Piper Sandler Analyst Lists
Piper Sandler analyst Brent A.
Hasbro’s Stock Outlook Dims: Analyst Downgrades To Neutral Amid Persisting Industry Headwinds
DA Davidson analyst Linda Bolton Weiser downgraded the shares of Hasbro Inc (NASDAQ: HAS) from Buy to Neutral and
Why Is Apple Stock Sliding Tuesday?
Apple Inc (NASDAQ: AAPL) stock is trading lower Tuesday after Barclays analyst Tim Long downgraded the stock from Equal-Weight to Underweight and lowered the price target
Lantheus Downgraded Due To Reliance On PNT2002; Analyst Cites Comparable Profile To Novartis’ Drug
Monday, Lantheus Holdings Inc (NASDAQ: LNTH) and POINT Biopharma Global Inc (NASDAQ: PNT) reported topline data from pivotal Phase 3 SPLASH trial of 177Lu-PNT2002 in metastatic c